Both T-cell ALL and B-lineage ALL cells can overexpress CD38 and are potential targets for treatment with daratumumab, which has been shown to have efficacy in adult cancers, especially in CD38+ multiple myeloma. This evidence concerns the gene CD38 and plasma cell myeloma.